![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/06/2875637/0/en/AsclepiX-Therapeutics-Completes-Enrollment-in-DISCOVER-Trial-for-Neovascular-Age-Related-Macular-Degeneration-nAMD.html
https://www.globenewswire.com/news-release/2023/07/26/2711155/0/en/AsclepiX-Therapeutics-Raises-10-Million-to-Advance-Phase-1-2a-Clinical-Study-of-AXT107.html
https://eyewire.news/articles/asclepix-therapeutics-doses-first-patient-in-phase-1-2a-trial-of-axt107-intravitreal-self-forming-gel-depot-peptide-for-dme/